Overview

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to find out if the combination of TAS 102 and Ramucirumab is safe and effective in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Phase:

Phase 2

Details

Lead Sponsor:

H. Lee Moffitt Cancer Center and Research Institute

Treatments:

Antibodies, Monoclonal
Ramucirumab
Trifluridine